secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2023-08-21T23:59:59+00:00
Accession:  0001104659-23-093684
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Apogee Therapeutics appoints Mark C. McKenna as Chairman of Board
-----------------------------------------------------------------

- Mark C. McKenna appointed as Chairman and Class III director, effective August 17, 2023.
- Former President, CEO, and Chairman of Prometheus Biosciences, acquired by Merck for ~$10.8B.
- Previously President of Salix Pharmaceuticals and senior roles at Bausch + Lomb and Johnson & Johnson.
- Annual compensation of $84,000 for Chair and committee roles; options for 50,000+100,000 shares vesting over 3 years.
- McKenna holds B.S. from Arizona State and MBA from Azusa Pacific; brings I&I development and commercial expertise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465923093684/0001104659-23-093684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465923093684/tm2324210d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-093684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer